Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
Authors not listed
Amoneta Diagnostics SAS · 2017
Abstract
The ADCHIP study (ST0067) is a non-interventional, monocentric, prospective study conducted by Amoneta Diagnostics and the Leenaards Memory Center (Lausanne, Switzerland). Its main objective is to develop and validate a microfluidic chip-based protocol that stabilizes human red blood cells for several weeks, enabling subsequent testing of blood biomarkers for Alzheimer's disease (AD) diagnosis.
This proof-of-performance study will include 150 well-characterized participants divided equally into three groups: 50 patients with Alzheimer's disease (AD), 50 with non-Alzheimer neurodegenerative diseases (NAD, including Parkinson's disease and frontotemporal dementia), and 50 healthy controls (HC).
The primary objective is to assess the diagnostic performance (sensitivity and specificity) of two main blood-based biomarkers-amyloid-β (Aβ) and protein kinase C (PKC)-measured using Amoneta's proprietary fluorescent assays and chip-cytometry technology. The secondary objective is to evaluate emerging biomarkers (proteins, RNA signatures, metabolomic and lipidomic profiles) for Alzheimer's disease detection.
No therapeutic intervention will be administered; only biological samples (blood and urine) will be collected. Results will be compared with existing clinical, imaging, and cerebrospinal fluid (CSF) biomarkers. The study aims to provide a reliable, non-invasive, and affordable blood test for early Alzheimer's diagnosis, with potential applications for patient stratification and therapeutic monitoring in future clinical trials.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Anonymous. (2017). A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease. <em>Amoneta Diagnostics SAS</em>. https://clinicaltrials.gov/study/NCT07307872
Vancouver
Anonymous. A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease. Amoneta Diagnostics SAS. 2017.
BibTeX
@misc{anon2017ABioma,
title = {A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease},
author = {Anonymous},
journal = {Amoneta Diagnostics SAS},
year = {2017},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Amoneta Diagnostics SAS 2019
Open access · US-GOV
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
Exonhit 2008
Open access · US-GOV
Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia : A Prospective Study for a Blood Diagnostic Test in Alzheimer's Disease - (Protocol n° EHTAD/002).
Assistance Publique - Hôpitaux de Paris 2021
Open access · US-GOV
Finding Retinal Biomarkers in Alzheimer's Disease
Indiana University 2023
Open access · US-GOV
DIGITAL Biomarker: Blood Based Biomarkers in the Primary Care Setting for Timely and Accurate Diagnosis of Alzheimer's Disease
Maastricht University Medical Center 2022
Open access · US-GOV
The TearAD Study: Tear Biomarkers for Alzheimer's Disease (AD) Screening and Diagnosis
Alzheimer s Research & Therapy 2023
Open access · CC-BY